To include your compound in the COVID-19 Resource Center, submit it here.

bluebird proposes $600M follow-on after ASH gains

bluebird bio Inc. (NASDAQ:BLUE) jumped $30.65 (18%) to $201.80 on Monday, adding over $1.4 billion in market cap, after reporting updated data from the Phase I CRB-401 trial evaluating its chimeric

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE